The North America Digital Health for Obesity Market offers growth opportunities via telehealth, AI-driven personalization, and FDA-cleared digital therapeutics. Key players enhance services with AI, ...

Marketers are positioning weight-loss shots as cosmetic elixirs for anyone who wants to lose a few pounds. Doctors warn that such patients could put themselves at risk for potentially serious side ...

Doctors warn that microdosing copycat Ozempic and other GLP-1s is not approved for people with low BMIs and carries risks of serious side effects like pancreatic damage.

Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization ...

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product ...

Hims & Hers Health, Inc. (NYSE: HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. • HIMS stock is racing ...

What To Know: The weakness appears linked to Novo Nordisk’s decision to slash the U.S. self-pay price of its popular GLP-1 drugs, Wegovy and Ozempic, from $499 to $349 per month, intensifying pressure ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Value Investor model based on the published strategy of ...

Nov 17 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, despite its bumpy ride over recent months. The San Francisco, CA-based health and ...

A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history.